MarketPulse
E

$EW

2 articles found
2 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Eric Trie

ORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Pulmonary Artery Catheter Market Projected to Expand 60% Through 2035

Pulmonary artery catheter market projected to grow from $1.23B to $1.97B by 2035, driven by rising cardiovascular disease and expanding critical care infrastructure globally.
MDTBSXEWBDXTFXmedical devicescardiovascular disease